A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care

NACompletedINTERVENTIONAL
Enrollment

400,415

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Breast Cancer
Interventions
BEHAVIORAL

Basic public reporting

The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.

BEHAVIORAL

Enhanced intervention

The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.

BEHAVIORAL

Control group - observational

"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

Wisconsin Collaborative for Healthcare Quality

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

Medical College of Wisconsin

OTHER

NCT02831439 - A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care | Biotech Hunter | Biotech Hunter